FY2026 Earnings Estimate for IPSEN Issued By HC Wainwright

IPSEN (OTCMKTS:IPSEY) – Investment analysts at HC Wainwright boosted their FY2026 earnings per share (EPS) estimates for IPSEN in a note issued to investors on Wednesday, November 11th. HC Wainwright analyst R. Selvaraju now forecasts that the company will earn $3.59 per share for the year, up from their previous forecast of $3.36. The consensus estimate for IPSEN’s current full-year earnings is $3.82 per share. HC Wainwright also issued estimates for IPSEN’s FY2027 earnings at $4.05 EPS.

Other equities analysts also recently issued research reports about the company. Barclays upgraded IPSEN from a “strong sell” rating to a “hold” rating in a research note on Thursday, September 17th. Jefferies Financial Group cut IPSEN from a “hold” rating to a “moderate sell” rating in a research report on Sunday, August 2nd. Two investment analysts have rated the stock with a Buy rating, three have assigned a Hold rating and two have given a Sell rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Hold”.

IPSEN Trading Up 0.6%

Shares of IPSEN stock opened at $46.72 on Thursday. IPSEN has a 12-month low of $34.34 and a 12-month high of $51.10. The stock has a fifty day simple moving average of $43.37 and a 200 day simple moving average of $45.43.

About IPSEN

IPSEN is a global biopharmaceutical company headquartered in France. Founded in 1929, it develops and commercializes medicines focused on oncology, rare diseases and neuroscience. Its portfolio includes treatments such as Somatuline for certain neuroendocrine tumors and acromegaly, Dysport for several neurological and aesthetic uses, and Cabometyx for certain cancers. The company also conducts research and development to advance medicines across its therapeutic areas. IPSEN serves patients and healthcare professionals in countries around the world through its international commercial operations and partnerships.